Geron Corporation’s Post

June 10-16 is International Men’s Health Week. Let's raise awareness about men's well-being. Read on for new research about screening for prostate cancer from the National Cancer Institute (NCI). "NCI-supported researchers have developed and validated a new #ProstateCancer urinary biomarker test that can help differentiate who should proceed for biopsy after an elevated prostate-specific antigen (PSA) test from those who can wait. #ProstateCancer" https://go.nih.gov/RaLuYUx

🆕#IARCpaper in The Lancet aims to evaluate which #HPV genotypes caused #CervicalCancer, as well as their carcinogenic strength and contribution to burden of #CxCa. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature: https://lnkd.in/dAGfNnYy

📣We share with you the #Article "Novel Insights into Redox-Based Mechanisms for Auranofin-Induced Rapid Cancer Cell Death" 🧐by Elie Hatem, et al. Université Paris-Saclay Access the full paper here▶️ https://lnkd.in/d4Afc5-A Keywords: auranofin; oxidative stress; redox regulation

You're all cordially invited to read “Effects of Regioisomerism on the Antiproliferative Activity of Hydroxystearic Acids on Human Cancer Cell Lines” 👉https://ow.ly/OYC750QgI4P #mdpimolecules #molecules_mdpi

Explore the latest breakthroughs in cancer research with our #TechnicalArticle looking into RAS and RAF target engagement (TE). Discover how NanoBRET® TE technology is not only advancing our capabilities in creating biologically relevant models, but also enriching our understanding of cancer's intricacies and the pathways of therapeutic resistance. https://bit.ly/3xVzBgC

💡 Explore our work developing a sophisticated model integrating the cell cycle and circadian rhythm. This innovative approach helps to pinpoint optimal drug delivery schedules to maximise effectiveness against cancer. https://lnkd.in/gixJGaQx

🧐Check out the #Review "Tau Protein as Therapeutic Target for Cancer? Focus on Glioblastoma" 👏by Hedna Rayane et al. Aix-Marseille University 🔗Access the full paper here: https://lnkd.in/dUzpXUHm Keywords: microtubule-associated protein Tau; glioblastoma; signaling pathway

RORs are emerging as a hot target in cancer research. While often dormant in healthy tissues, they're activated in many cancers. At OriGene, we are dedicated to supporting this vital area of research by providing a comprehensive range of high-quality products: ✔️cDNA Clones ✔️Lentiviral Particles ✔️Antibodies ✔️CytoSections ✔️OEL Controls With the help of OriGene’s validated tools, researchers can drive significant advancements in understanding ROR pathways and their potential as therapeutic targets. Click here to learn more: https://hubs.ly/Q02KMk8P0

Advancements in isothermal amplification technologies are fueling new diagnostic and clinical approaches for pathogen detection and cancer research. This one was a bear to write but really proud of how it turned out. Download and read to learn more! https://lnkd.in/gaRUhBYJ

Excited for Professor Melissa Fullwood's lab's presentation at the EMBO Chromatin Biology in Cancer Workshop! If you're attending, come listen to Dr. Seng Chuan Tang's talk in Session 6, April 26th. Dr. Tang will discuss epigenetic therapies and drug resistance, providing insight into the disruption of super-silencers by EZH2 and REST inhibition, altering chromatin interactions, and impeding cancer growth. #CancerResearch